Clinical Trial Update: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating maximal tolerated dose, safety, and efficacy of CPI-613 (Devimistat) with hydroxychloroquine in relapsed or refractory clear cell sar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Sarcoma of Soft Tissue
• Sarcoma

Drugs mentioned

• CPI-613 (devimistat) (devimistat)
• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Cornerstone Pharmaceuticals | Conditions: Sarcoma, Clear Cell | Phase 1, Phase 2 | Status: COMPLETED